StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Cantor Fitzgerald Positive on Lucid Diagnostics Inc (LUCD) Following Earnings
August 13, 2024 2:57 PM
Cantor Fitzgerald analyst Ross Osborn reiterated an Overweight rating and $3.00 price target on Lucid Diagnostics Inc (NASDAQ: LUCD).The analyst ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Next Articles
Lucid Diagnostics Inc (LUCD): American Foregut Society Formally Requests Medical Policy Coverage of EsoGuard® to Enhance Early Detection of Esophageal Cancer
August 13, 2024 8:27 AM
The American Foregut Society Formally Requests Medical Policy Coverage of EsoGuard® to Enhance Early Detection of Esophageal Cancer
August 13, 2024 8:16 AM
PAVmed Provides Business Update and Second Quarter 2024 Financial Results
August 13, 2024 8:01 AM
Needham Reiterates Buy Rating on Lucid Diagnostics Inc (LUCD)
August 12, 2024 4:47 PM
Lucid Diagnostics Inc. (LUCD) Reports In-Line Q2 EPS
August 12, 2024 9:47 AM
Form 10-Q Lucid Diagnostics Inc. For: Jun 30
August 12, 2024 8:32 AM
Form 8-K Lucid Diagnostics Inc. For: Aug 12
August 12, 2024 8:16 AM
Lucid Diagnostics Provides Business Update and Second Quarter 2024 Financial Results
August 12, 2024 8:07 AM
